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Abstract. 
Adenoid cystic carcinoma is rare and usually arises in the salivary glands. It grows slowly, 
but is characterized by easy perineural invasion with local infiltration and distant metastasis. In 
metastatic setting, the efficacy of intravenous chemotherapy is limited. Herein, we report one 
male patient who had a advanced, inoperable adenoid cystic carcinoma with lung metastasis, 
presenting with right buccal unhealed ulcer, pain and poor intake, whose loco-regional tumors 
responded dramatically after intra-arterial chemotherapy and his symptoms were almost com-
pletely relieved. We also make a literature review for treatment of adenoid cystic carcinoma. 
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病例報告  
局部晚期無法開刀之腺樣囊狀癌經動脈化療後腫瘤明顯縮小 
薛富仁 黃懷正 洪瑞隆* 
國立台灣大學醫學院附設醫院 腫瘤醫學部 
中文摘要 
  腺樣囊狀癌發生率不高且好發於唾液腺。其生長緩慢，卻易沿著神經局部侵犯並遠
處轉移；全身轉移後往往對靜脈化學治療反應不佳。本篇文章描述一位病患以右側疼痛
之口腔潰瘍及食慾不佳為表現，被診斷為局部晚期無法開刀併肺部轉移之腺樣囊狀癌。
經動脈化學治療後，其局部腫瘤明顯縮小且症狀幾乎完全消失。我們亦對腺樣囊狀癌治
療做文獻回顧。 
 
關鍵字: 腺樣囊狀癌、經動脈化學治療 
 
INTRODUCTION 
Adenoid cystic carcinoma (ACC) is a rare variant 
of adenocarcinoma. It usually arises in the salivary 
glands, and occasionally originates in aerodigestive 
tract, breast, cervix, and Bartholin’s glands. Less than 
60 new cases are diagnosed in Taiwan each year [1]. 
Although it grows slowly, ACC is characterized by 
easy perineural invasion, which results in a high rate 
of local recurrence and distant metastasis [2]. In this 
setting, chemotherapy is of limited benefit [3]. We 
describe a patient with locally advanced, inoperable 
ACC and lung metastasis, who had dramatic local 
tumor shrinkage after intra-arterial chemotherapy 
(IACT).  
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CASE REPORT 
This 58 years-old man, a heavy smoker for 40 
years, had been well until 2009, when a right buccal 
unhealed ulcer developed. He ignored it initially, but 
masses in the right mouth floor and neck began to en-
large in 2012. There was associated odynophagia and 
dysphagia, resulting in a weight loss of 18 kilograms 
in one year. He visited the dental clinic of our hospital 
in April, 2013, where a huge indurated mass in the 
right mouth floor and multiple lymphadenopathies on 
the right of the neck were found. Head and neck mag-
netic resonance imaging (MRI) revealed one huge 
mass involving the right ventral tongue, sublingual, 
submandibular, and masticator space, and the tumor 
measured about 9 cm in its greatest diameter (Figure 
1A). There were several necrotic cervical lymph nodes 
at levels II-III on the right, measuring up to 3 cm 
(Figure 1B). Incisional biopsy of mouth floor tumor 
disclosed ACC, with trabecular, tubular, and cribri-
form appearance. Focal perineural invasion was also 
found (Figure 2). A chest X-ray showed bilateral mul-
tiple lung nodules, suggesting metastasis (Figure 3A). 
Abdominal computed tomography revealed suspected 
hepatic hemangioma and a bone scan showed no bone 
metastasis. The diagnosis of mouth floor ACC with 
lung metastasis, cT4bN2bM1, was made. 
Our treatment goal focused on loco-regional tumor 
control because lung metastasis was symptom-free 
and the natural course of ACC is usually indolent. 
IACT was chosen to achieve the goal since it is known 
to increase anti-tumor activity in head and neck can-
cers [4,5]. Bevacizumab, a monoclonal antibody 
against vascular endothelial growth factor (VEGF), 
was added in our regimen because it may increase 
delivery of chemotherapy to the tumor site [6]. Radi-
otherapy was not given for concern of related side 
effects. The patient received IACT (mitomycin 8 mg/ 
m2 infusion for 10 minutes ; cisplatin 80 mg/m2 infu-
sion for 1 hour ; bevacizumab 200 mg infusion for 1 
hour on day 1, every three weeks) for two cycles, with 
the catheter tip anchored at the right lingual artery 
during the first cycle (May, 2013) and right facial ar-
tery during the second cycle (June, 2013) transiently. 
The tumor and neck lymphadenpathies became small-
er grossly and odynophagia improved. His oral intake 
also increased and body weight was gradually re-
gained. Follow with head neck MRI showed dramatic 
shrinkage of the mouth floor tumor (Figure 1C, 1D). 
Lung nodules on the chest X-ray, however, remained 
stationary (Figure 3B). The patient tolerated the pro-
cedures well except for skin pigmentation and one 
episode of mild oral tumor bleeding after the second 
cycle IACT, which resolved after bosmin gauze pack-
ing and transamine use. The patient remained symp-
tom-free for six months, followed by enlarging neck 
lymphadenopathies (4 cm to 6 cm in 3 months) and 
more advanced lung metastasis. He underwent another 
course of IACT on April, 2014 and the neck mass was 
flatter. 
 
DISCUSSION 
ACC accounts for around 10% of malignant sali-
vary gland cancers. In 25% of cases, it arises from the 
major salivary glands and in 40-50% from the minor 
salivary glands. The tumor is composed of basaloid 
cells with small, angulated, hyperchromatic nuclei, 
and scant cytoplasm. There are three histological pat-
terns, including cribriform, tubular, and solid; howev-
er, their prognostic significance remains undetermined 
[7].  
The natural course of ACC is indolent, but it is 
characterized by easy perineural invasion, locoregion-
al recurrence, and distant metastasis. For patients 
without distant metastasis, the 10-year overall survival 
rate is roughly 50%. Nevertheless, when metastasis is  
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Figure 1. The head and neck magnetic resonance imaging (MRI) before intra-arterial chemotherapy (IACT) 
showed main tumor (arrow) (A,B) and lymphadenopathies (star) (B). After IACT, MRI showed   
dramatic tumor shrinkage (C, D) 
 
 
present, the median overall survival is about 3 years 
[3]. 
Surgical resection is the mainstay of curative 
treatment for operable, locoregional disease. In the 
National Cancer Institute’s Surveillance, Epidemiolo-
gy, and End Results (SEER) program from 1937 to 
2004, 2286 patients with head and neck ACC were 
analyzed [8]. Among them, only 8% had nodal in-
volvement and 2.4% had distant metastasis. All pa-
tients underwent surgical intervention and 61% re-
ceived external beam radiotherapy (EBRT). For pa-
tients with neither nodal involvement nor distant me-
tastasis, the overall survival rates for 5, 10, 15, and 20 
years were 77.3%, 59.3%, 44.9%, and 35% respec-
tively. However, for patients with nodal involvement, 
the overall survival rates for 5, 10, and 15 years were 
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Figure 2. Hematoxylin and eosin stain of the tumor 
(arrow), 100X (A). Cribriform pattern, 
200X (B). Perineural invasion (arrow), 
400X (C) 
 
 
55.2%, 30.7%, and 16.2% only. A Cox proportional- 
hazards model showed that higher T classification, 
nodal involvement, distant metastasis, high grade his-
tology, and increasing age were associated with poor 
prognosis. In addition, adjuvant EBRT was suggested 
for patients with positive surgical margin to increase 
locoregional control [9]. 
For inoperable disease, EBRT is a treatment option. 
In one retrospective study reported by William et al., 
the 5-year local control rate for T4 disease after EBRT 
was 44% [10]. The 5-year overall survival was around 
25-50% [10,11]. IACT with concurrent EBRT had 
also been reported by Makoto et al. for two cases of 
inoperable maxillary sinus ACC [12]. During the pro-
cedure, two catheters were inserted superselectively 
into the maxillary artery via the superficial temporal 
arteries bilaterally. The patients received IACT during 
EBRT with docetaxel and cisplatin at doses of 15 
mg/m2/week and 5 mg/m2/day respectively. Concur-
rent EBRT was given 5 times per week at 2 Gray per 
fraction, for a total of 60 Gray. Both of them showed 
dramatic tumor shrinkage, but had grade 3 adverse 
effects of stomatitis and neutropenia. One patient had 
complete response for 20 months and the other had a 
partial response for 6 months.  
IACT alone has been described for cytoreduction 
of lacrimal ACC before definitive treatment [13]. It is 
potentially an effective method to improve local dis-
ease control and disease-free survival. However, there 
is no report regarding IACT for inoperable head and 
neck ACC. To the best of our knowledge, the case we 
report herein is the first one to demonstrate a dramatic 
response after IACT for inoperable head and neck 
ACC. 
In metastatic setting, intravenous chemotherapy 
has been used. The response rate of single-agent cyto-
toxic drugs, such as cisplatin, mitoxantrone, epirubicin, 
and vinorelbine, is about 10-15%. For cytotoxic 
agents given in combination, cisplatin and doxorubi-
cin are the most commonly used drugs and the re-
sponse rate is around 25% [3]. Lung metastasis in our 
patient remained stationary for 6 months after two 
cycles of IACT, which progressed gradually along 
A 
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Figure 3. Chest X-ray showed bilateral multiple lung 
nodules (A). After IACT, lung nodules re-
mained stationary (B) 
 
 
with enlarging neck lymphadenopathies. Since the 
growth rate differed, we think IACT still had some 
systemic anti-tumor effect, resulting in controlled lung 
metastasis. 
Although ACC has various degrees of expression 
of c-kit, VEGF, epidermal growth factor receptor 
(EGFR), and HER-2, the response of targeted thera-
pies, such as imatinib, sunitinib, sorafenib, gefitinib, 
cetuximab, and lapatinib, are poor. Most of the cases 
show a best response of stable disease at best [3,14, 
15]. There are many reasons why clinical trials fail to 
demonstrate efficacy of targeted therapies. First, the 
indolent course of ACC is a major factor. Timing of 
response evaluation warrants reconsideration. Second, 
a lack of predictive biomarkers and driver mutations is 
an obstacle to define truly responsive patients. Last, it 
is difficult to unify inclusion criteria because ACC is a 
rare disease. Different histological patterns, undefined 
prior therapies and disease status all account for dif-
ferent outcome. 
Recently, the exome or whole-genome profiling of 
ACC has been reported [16-18], including mutations 
associated with chromatin state regulators and fibro-
blast growth factor receptor (FGFR) mutation or am-
plification. Dovitinib, a multiple kinase inhibitor in-
volving the FRFR and VEGF receptors, has been used 
in metastatic ACC [19]. In the study, 21 patients who 
progressed in the last 6 months after chemotherapy, 
radiotherapy or targeted therapies, were treated with 
dovitinib 500 mg daily with 5 days on/2 days off 
schedule. Among 19 evaluable patients, 2 had a partial 
response (11%), with time to progression at 5 months 
and 8 months respectively. 
In conclusion, we have reported a case, probably 
the first in the literature, with locally advanced, inop-
erable head and neck ACC, who had dramatic loco- 
regional tumor shrinkage after IACT. Since ACC was 
found not chemo-sensitive, the whole genome profil-
ing was uncovered to detect actionable genomic alter-
ations. Among them, FGFR mutation or amplification 
had been identified and dovitinib had efficacy for 
metastatic ACC. 
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